Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022
L Torres-Canchala, D Cleves-Luna… - Children, 2022 - mdpi.com
Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known
cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy …
cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy …
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience
Objectives Medical therapies to limit disease recurrence are critically needed for recurrent
respiratory papillomatosis (RRP). Systemic bevacizumab is emerging as an exciting …
respiratory papillomatosis (RRP). Systemic bevacizumab is emerging as an exciting …
[HTML][HTML] Recurrent Laryngeal Papillomatosis: A Laser CO2 Surgery and Bevacizumab Intralesional Injection as Adjuvant Therapy
C Galletti, G Bruno, F Ciodaro, F Galletti - An International Journal of …, 2022 - aijoc.com
We present a case of recurrent respiratory papillomatosis (RRP) transformed in a lobular
intraepithelial neoplasia LIN 2 vocal fold lesion treated with a microdirect laryngoscope with …
intraepithelial neoplasia LIN 2 vocal fold lesion treated with a microdirect laryngoscope with …